Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Operating Expenses (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Operating Expenses for 6 consecutive years, with $56.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 1.15% year-over-year to $56.3 million, compared with a TTM value of $223.9 million through Dec 2025, changed 0.02%, and an annual FY2025 reading of $223.9 million, changed 0.02% over the prior year.
  • Operating Expenses was $56.3 million for Q4 2025 at Treace Medical Concepts, up from $55.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $59.9 million in Q1 2024 and bottomed at $16.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $44.9 million, with a median of $49.3 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 189.47% in 2021, then decreased 4.13% in 2025.
  • Year by year, Operating Expenses stood at $33.7 million in 2021, then skyrocketed by 35.19% to $45.5 million in 2022, then rose by 26.39% to $57.5 million in 2023, then decreased by 3.21% to $55.7 million in 2024, then increased by 1.15% to $56.3 million in 2025.
  • Business Quant data shows Operating Expenses for TMCI at $56.3 million in Q4 2025, $55.4 million in Q3 2025, and $54.7 million in Q2 2025.